Black Diamond (BDTX) director receives 6,919-share stock grant

Rhea-AI Filing Summary

Behbahani Ali reported acquisition or exercise transactions in this Form 4 filing.

Black Diamond Therapeutics director Ali Behbahani received a grant of 6,919 shares of common stock on March 20, 2026. The award was made under the company’s non-employee director compensation policy, as he elected to take stock instead of cash fees for his annual board service.

The grant was valued at $2.15 per share, based on the closing market price on March 19, 2026. After this award, Behbahani directly holds 93,568 common shares. The filing also reports 4,448,757 shares held indirectly through New Enterprise Associates 16, L.P., where he disclaims beneficial ownership for portions in which he has no pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Behbahani Ali

(Last) (First) (Middle)

2855 SAND HILL RD

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/20/2026		A(1)		6,919	A	$2.15(2)	93,568	D
Common Stock								4,448,757	I	See Note 3(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 19, 2026.

3. The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.

	/s/ Zachary Bambach, attorney-in-fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Black Diamond Therapeutics (BDTX) director Ali Behbahani report on this Form 4?

Ali Behbahani reported receiving 6,919 shares of common stock. The shares were granted as compensation for his annual service as a non-employee director, taken in stock instead of cash under the company’s director compensation policy.

At what price was the Black Diamond Therapeutics (BDTX) stock grant to Ali Behbahani valued?

The 6,919-share grant was valued at $2.15 per share. This price reflects the closing market price of Black Diamond Therapeutics common stock on March 19, 2026, which the company used to determine the value of the stock compensation.

How many Black Diamond Therapeutics (BDTX) shares does Ali Behbahani hold directly after this grant?

After the grant, Behbahani directly holds 93,568 common shares. This total includes the 6,919 shares he received as stock compensation in lieu of cash fees for his annual service on Black Diamond Therapeutics’ board.

What indirect holdings related to Black Diamond Therapeutics (BDTX) are disclosed for Ali Behbahani?

The filing shows 4,448,757 shares held indirectly through NEA 16. These shares are owned by New Enterprise Associates 16, L.P., and Behbahani disclaims beneficial ownership for portions in which he has no pecuniary interest under Section 16 rules.

Was the Black Diamond Therapeutics (BDTX) Form 4 transaction a market purchase or sale by Ali Behbahani?

The reported transaction was a stock grant, not a market trade. Behbahani received 6,919 shares as a compensation award for board service, rather than buying or selling shares in the open market.

Why did Ali Behbahani receive Black Diamond Therapeutics (BDTX) shares instead of cash?

He elected to receive shares under the company’s director compensation policy. Black Diamond Therapeutics allows non-employee directors to choose stock in lieu of cash fees for annual board service, aligning director pay more closely with shareholder interests.